Acrivon reports Q2 2026 results, flags ACR-368 interim data for second half of 2026

Acrivon Therapeutics reported second quarter 2026 financial results on August 12, 2026, alongside updates on its two clinical programs. The company said the prespecified interim analysis of the registrational-intent, all-comer, serous endometrial cancer arms of the Phase 2b study for ACR-368 remains a focus for the second half of 2026.¹ Dosing is ongoing in both endometrial cancer arms, with Arm 4 as a single agent and Arm 3 combining ultra-low dose gemcitabine sensitization, across US and European sites.¹ Acrivon said it expects to complete enrollment of Arm 3 or Arm 4 by the fourth quarter of 2026, based on the interim data read-out, and to initiate a Phase 3 confirmatory trial in the first half of 2027.¹

For ACR-2316, a WEE1/PKMYT1 inhibitor, Acrivon said the Phase 1/2 study advanced into the randomized dose expansion stage, supported by an observed favorable safety profile and durable antitumor activity, with the expansion phase evaluating 120 mg and 160 mg oral once-daily doses on a 3 days on, 4 days off weekly schedule.¹ That expansion phase will assess safety and activity in patients with AP3-identified, molecularly-defined lung, endometrial, cervical, and esophago-gastric junction cancers.¹ The company also said it plans to submit an IND filing to the FDA for its CDK11 inhibitor development candidate in the first half of 2027.¹

On financials, Acrivon reported a net loss of $18.0 million for the quarter ended June 30, 2026, compared to a net loss of $21.0 million for the same period in 2025.¹ As of June 30, 2026, the company said it had cash, cash equivalents and investments of $90.0 million, which is expected to fund operating expenses and capital expenditure requirements into the fourth quarter of 2027.¹